Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 5spartalizumab 2durvalumab 2Immunohistochemistry 2Gemcitabine 2130-nm albumin-bound paclitaxel 2tremelimumab 1obinutuzumab 1naptumomab estafenatox 1liposomal doxorubicin 1elgemtumab 1Polymerase Chain Reaction 1Oxaliplatin 1Nivolumab 1Mass Spectrometry 1Leucovorin 1LGK974 1Itraconazole 1In Situ Hybridization, Fluorescence 1Fulvestrant 1Fluorouracil 1EC regimen 1Cisplatin 1Carboplatin 1CP protocol 1Biopsy 1Bevacizumab 1Albumin-Bound Paclitaxel 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × LGK974 × Breast × Clear all
NCT01351103 2025-06-13

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Novartis

Phase 1 Completed
185 enrolled
BreastDermatologicGastrointestinal

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡